HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CNS Breathe Right Sales, FiberChoice Cuts Produce "Return To Profitability"

This article was originally published in The Tan Sheet

Executive Summary

CNS expects FiberChoice to become a $30 mil. product in the long term, which would equate to about 10% of the fiber category, the company said.

You may also be interested in...

CNS International Growth, Ad/Promo Cuts Key Strategies For FY 2003

CNS aims to increase international sales by up to 20% in 2002 as part of its strategy to boost revenue and continue recent earnings gains

CNS Restructuring Plan Focused On Bolstering Breathe Right Sales

CNS recorded a $1.2 mil. charge against earnings in the second quarter as part of a restructuring plan aimed at strengthening its core Breathe Right nasal strip business and returning the firm to sustainable profitability.

Breathe Right Children's Products Provide "Drug-Free" Cold Remedy

CNS' two new children's Breathe Right nasal strips, now reaching food, drug and mass outlets nationwide, offer a new solution for the "winter woes of a stuffy nose," according to the company.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts